Key points from article :
More than 5,000 patients with metastatic disease recruited from four large multi-centre global clinical trials. Some patients who would receive no benefit could skip three months of unnecessary treatment.
The days when everyone was treated with the same drug are gone.
The study was published in The Lancet Oncology journal.
